Analyst firms · Wolfe Research · SHC
Wolfe Research SHC price target and rating history
Sotera Health Company (SHC) · Health Care
Wolfe Research rates Sotera Health Company (SHC) Outperform with a $25 price target, as of its latest action on Jan 11, 2023. It has published 3 rating actions on SHC since April 2022, including 1 upgrade and 1 downgrade. Across 4 firms with a SHC price target in the last 12 months, the median target is $22.
- Current rating
- Outperform
- Price target
- $25
- Median target, all firms
- $22
- Actions on SHC
- 3
Wolfe Research price target on SHC
Every Wolfe Research rating on SHC
- Jan 11, 2023
- Jun 9, 2022
- Apr 6, 2022
How other firms rate SHC
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Goldman Sachs | Buy | $20 | Jun 5, 2026 |
| Piper Sandler | Overweight | $24 | Jan 9, 2026 |
| RBC Capital Markets | Outperform | $24 | Jan 9, 2026 |
| William Blair | Outperform | Dec 18, 2025 | |
| BMO Capital Markets | Outperform | $19 | Nov 13, 2025 |
Questions about Wolfe Research and SHC
- What is Wolfe Research's price target for SHC?
- Wolfe Research's latest stated price target for Sotera Health Company (SHC) is $25, from its action on Jan 11, 2023.
- What is Wolfe Research's rating on SHC?
- Wolfe Research rates SHC Outperform, a bullish rating, as of Jan 11, 2023.
- When did Wolfe Research last change its view on SHC?
- On Jan 11, 2023, Wolfe Research upgrades to Outperform from Peer Perform, price target $25.
- How does Wolfe Research's SHC target compare with other analysts?
- Across 4 firms with a SHC price target in the last 12 months, the median target is $22.
More SHC rating histories
All Wolfe Research ratingsSHC news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.